Pharmacyclics (PCYC) signed rights to its blood-cancer drug PCI-32765 to Johnson & Johnson (JNJ) for a whopping $150m. This is a big deal for a growing biotech company and ensures that it now has one of the best pharma customers in the world. http://ow.ly/7XH94
